KIND-002 is expected to be a major new therapy for severe cutaneous diseases in dogs
SAN FRANCISCO, California. (February 3, 2013) – Kindred Biosciences, Inc. (KindredBio) announced today the filing of an Investigational New Animal Drug Application (INAD) with the U.S. Food and Drug Administration (FDA) for KIND-002. KIND-002 is a potent molecule being developed for severe dermatological diseases in dogs.
- Kindred Biosciences Announces Acquisition of Kansas Manufacturing Plant and Execution of Commercial Manufacturing Agreement for ZimetaJune 26, 2017 - 7:33 am
- Kindred Biosciences Added to the Russell 2000 IndexJune 15, 2017 - 12:32 am
- Kindred Biosciences to Present Data from Six Studies at the 2017 American College of Veterinary Internal Medicine ConferenceMay 30, 2017 - 9:01 am